FDA says Qinprezo not ready for NDA; Sunesis slammed
This article was originally published in Scrip
Shares of Sunesis Pharmaceuticals plummeted nearly 67% in after-hours trading on 23 July after it revealed the FDA wants more data before the agency would consider reviewing an application for the company's experimental acute myeloid leukemia (AML) drug Qinprezo (vosaroxin).
You may also be interested in...
The Medicines Company, Amarin and Geron have all reported interim analyses for clinical studies recently and investors have been left disappointed. Were we better off without the interim analysis?
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.